. Author manuscript; available in PMC: 2016 Mar 1.

Published in final edited form as: Pediatr Infect Dis J. 2015 Mar;34(3):e41–e43. doi: 10.1097/INF.0000000000000557

Table 2.

Findings from our previously reported clinical trial⁶ using the estimated minimal important difference (MID) of the Version 4 AOM-SOS scale to define failure of symptoms to improve appreciably.

Outcome Measure	Amoxicillin-Clavulanate Group^†	Placebo Group^†	P value
	Proportion (%)
Failure of symptoms to improve appreciably on Day 5^*	30/132 (23)	41/130 (32)	0.14
Failure of symptoms to improve appreciably on Day 7	16/130 (12)	30/126 (24)	0.02
Failure of symptoms to improve appreciably during Days 4 to 7	38/136 (28)	55/137 (40)	0.046

AOM-SOS denotes Acute Otitis Media Severity of Symptoms.

Day 1 was the day of enrollment.

^†

4 and 6 children in the amoxicillin-clavulanate and placebo groups, respectively, were lost to follow-up.